PROTAGONIST THERAPEUTICS, INC. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↑+557.0% +$153M
$125M
Free Cash Flow↑+53.5% +$166K
$-144K
Investing Cash Flow
$49M
Financing Cash Flow↓-29.6% -$1M
$3M
Capex↓-53.5% -$166K
$144K
Stock-Based Comp↑+17.7% +$2M
$11M
Debt Issued
—
Debt Repaid
—
D&A↑+218.6% +$258K
$376K
SBC Allocated Expense↑+17.7% +$2M
$11M
SBC Unrecognized Cost↑+4220.0% +$21M
$22M